cisplatin + sunitinib malate + tamoxifen citrate
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Intraocular Melanoma
Conditions
Intraocular Melanoma
Trial Timeline
May 1, 2007 → —
NCT ID
NCT00489944About cisplatin + sunitinib malate + tamoxifen citrate
cisplatin + sunitinib malate + tamoxifen citrate is a phase 2 stage product being developed by Pacific Biosciences for Intraocular Melanoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT00489944. Target conditions include Intraocular Melanoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00489944 | Phase 2 | UNKNOWN |
Competing Products
6 competing products in Intraocular Melanoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Mirabegron + Placebo | Astellas Pharma | Phase 1 | 33 |
| AZD4017 + Placebo + AZD4017 + Placebo | AstraZeneca | Phase 2 | 52 |
| ipilimumab + Tyrosinase/gp100/MART-1 Peptides | Bristol Myers Squibb | Phase 2 | 51 |
| OMS302 + Placebo | Omeros Corporation | Phase 3 | 72 |
| Part 1 OMS302 + Part 2 OMS302 + Part 2 Placebo | Omeros Corporation | Phase 3 | 72 |
| OMS302 + Placebo | Omeros Corporation | Phase 3 | 72 |